The Effect of Bevacizumab on Corneal Neovascularization
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
Eight patients with corneal neovascularization were treated with subconjunctival injection of
1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent
corneal neovascularization for at least 6 months unresponsive to other treatments. Patients
were monitored by ophthalmic exam and anterior segment photography.